F Andre

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Breast cancer with synchronous metastases: trends in survival during a 14-year period
    Fabrice Andre
    Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    J Clin Oncol 22:3302-8. 2004
  2. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
  3. ncbi request reprint Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
    F Andre
    Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:vi46-51. 2012
  4. doi request reprint Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer
    F Andre
    Department of Medical Oncology, Institute Gustave Roussy, Villejuif, France
    Ann Oncol 23:2059-64. 2012
  5. doi request reprint Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups
    Fabrice Andre
    Department of Medical Oncology, Institut National de la Sante et de la Recherche Medicale, France
    Clin Cancer Res 18:1555-60. 2012
  6. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
  7. doi request reprint Biomarker studies: a call for a comprehensive biomarker study registry
    Fabrice Andre
    Department of Medical Oncology and INSERM U981 Institut Gustave Roussy, 39 rue Camilles Desmoulins, Villejuif 94805, France
    Nat Rev Clin Oncol 8:171-6. 2011
  8. doi request reprint Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
    Fabrice Andre
    Breast Cancer Unit, Department of Medical Oncology, University Paris XI and Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 28:5110-5. 2010
  9. doi request reprint Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, France
    Curr Opin Oncol 22:547-51. 2010
  10. pmc Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 15:476-83. 2010

Detail Information

Publications85

  1. ncbi request reprint Breast cancer with synchronous metastases: trends in survival during a 14-year period
    Fabrice Andre
    Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    J Clin Oncol 22:3302-8. 2004
    ..This study sought to determine whether survival has improved over time for breast cancer patients who had metastases at diagnosis...
  2. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
    ..We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer...
  3. ncbi request reprint Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
    F Andre
    Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:vi46-51. 2012
    ..Improved treatment may be facilitated by biomarker-led understanding of subgroup molecular targets, which may predict benefit from currently approved agents, as well as newer targeted drugs...
  4. doi request reprint Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer
    F Andre
    Department of Medical Oncology, Institute Gustave Roussy, Villejuif, France
    Ann Oncol 23:2059-64. 2012
    ..The purpose of this study was to evaluate the prognostic and predictive value of p27 expression in patients with early breast cancer...
  5. doi request reprint Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups
    Fabrice Andre
    Department of Medical Oncology, Institut National de la Sante et de la Recherche Medicale, France
    Clin Cancer Res 18:1555-60. 2012
    ..The programs are being run by cooperative groups...
  6. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  7. doi request reprint Biomarker studies: a call for a comprehensive biomarker study registry
    Fabrice Andre
    Department of Medical Oncology and INSERM U981 Institut Gustave Roussy, 39 rue Camilles Desmoulins, Villejuif 94805, France
    Nat Rev Clin Oncol 8:171-6. 2011
    ..The benefits of a comprehensive biomarker study registry include more balanced evaluation of proposed markers, fewer false positive leads in research, and hopefully more rapid identification of promising candidate biomarkers...
  8. doi request reprint Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
    Fabrice Andre
    Breast Cancer Unit, Department of Medical Oncology, University Paris XI and Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 28:5110-5. 2010
    ....
  9. doi request reprint Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, France
    Curr Opin Oncol 22:547-51. 2010
    ..This review will summarize recent advances concerning the implication of tumor microenvironment in the response to chemotherapy...
  10. pmc Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 15:476-83. 2010
    ..In the present study, we assessed the efficacy of docetaxel in patients with metastatic breast cancer according to ER expression...
  11. ncbi request reprint Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer
    Fabrice Andre
    Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, Villejuif, France
    J Clin Oncol 23:2996-3000. 2005
    ..We have evaluated whether the mitotic index could predict the benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer who are eligible for adjuvant chemotherapy according to Saint Gallen guidelines...
  12. doi request reprint Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
    Fabrice Andre
    Translational Research Unit, UPRES03535, Paris Sud University, Orsay, France
    Clin Cancer Res 15:441-51. 2009
    ..We used high-resolution oligonucleotide comparative genomic hybridization (CGH) arrays and matching gene expression array data to identify dysregulated genes and to classify breast cancers according to gene copy number anomalies...
  13. ncbi request reprint Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
    F Andre
    Department of Medicine and Translational Research Unit UPRES03535, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:945-51. 2006
    ..In the present study, we evaluated the association between the chemokine receptors expressed in primary tumor cells and the site of metastatic relapse in patients with breast cancer...
  14. ncbi request reprint Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
    F Andre
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 18:2981-9. 2000
    ..We analyzed the prognosis of patients with resected N2 NSCLC to propose homogeneous patient subgroups...
  15. doi request reprint [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status]
    Y Bensouda
    Departement de Medecine, Comité de Pathologie Mammaire, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 96:923-8. 2009
    ..003). these data confirm that CA 15-3 is very variably elevated at time of metastatic relapse of breast cancer, and this is dependant on HR status...
  16. ncbi request reprint Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
    F Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:315-20. 2008
    ..We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues...
  17. ncbi request reprint Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
    R Conforti
    Translational Research Unit, Unité Propre de Recherche de l Enseignement Supérieur, équipe d accueil 03535, Villejuif, France
    Ann Oncol 18:1477-83. 2007
    ..The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy...
  18. doi request reprint p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
    F C Bidard
    Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1261-5. 2008
    ..We analysed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification...
  19. ncbi request reprint Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    C Mazouni
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:874-80. 2007
    ....
  20. ncbi request reprint Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays
    M Zoubir
    Institut Gustave Roussy, Villejuif, France University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 26:560. 2008
    ..560 Background: The goal of this study was to identify predictive biomarkers for the efficacy of preoperative endocrine therapy (ET)...
  21. ncbi request reprint p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
    F Bidard
    Institut Gustave Roussy, Vilejuif, France Centre Jean Perrin, Clermont Ferrand, France
    J Clin Oncol 26:608. 2008
    ..We analyzed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification...
  22. doi request reprint ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
    B Besse
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 22:575-81. 2011
    ..We hypothesised that there might be an increased incidence of BMs in ERCC1-negative non-SCCs when treated with adjuvant cisplatin-based chemotherapy...
  23. ncbi request reprint A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC)
    F Andre
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Centre René Gauducheau, Saint Herblain, France Institut Claudius Regaud, Toulouse, France Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain David Geffen School of Medicine, University of California, Los Angeles, CA Royal Marsden Hospital, London, United Kingdom University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA Novartis Pharmaceuticals Corporation, East Hanover, NJ
    J Clin Oncol 29:289. 2011
    ..Dovitinib (TKI258) is a multitargeted tyrosine kinase inhibitor that demonstrated potent antitumor activities in FGFR1-amplified tumor cell lines. This phase 2 study evaluated the efficacy and safety of dovitinib in metastatic HER2- BC...
  24. ncbi request reprint Predictive value of MRP2, p53, bcl2 and topoisomerase II immunostainings for the efficacy of anthracyclines-based adjuvant chemotherapy in breast cancer: Results from two randomized trials
    R Conforti
    Institut Gustave Roussy, Villejuif Cedex, France
    J Clin Oncol 26:616. 2008
    ..We evaluated the predictive value of MRP2, bcl2, topoisomerase IIα (Topo IIα) expression and p53 status for the efficacy of adjuvant anthracyclines (A)-based chemotherapy...
  25. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  26. ncbi request reprint High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer
    V Lazar
    Gustave Roussy Institute, Villejuif, France University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 26:547. 2008
    ..The aim of the present study was to identify new therapeutic targets, specific indications for existing targeted therapies, and to develop predictor for efficacy of preoperative chemotherapy...
  27. doi request reprint Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy
    M C Mathieu
    Breast Cancer Unit, Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:2046-52. 2012
    ..Breast Cancer Index (BCI) predicts recurrence risk in estrogen receptor+lymph node-breast cancer. Performance of BCI to predict chemosensitivity based on pathological complete response (pCR) and BCS was assessed...
  28. ncbi request reprint What can breast cancer molecular sub-classification add to conventional diagnostic tools?
    F Andre
    Breast Cancer Unit and Translational Research Unit, Institut Gustave Roussy, Villejuif
    Ann Oncol 18:ix33-6. 2007
  29. ncbi request reprint Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?
    F Andre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Cancer 91:2394-400. 2001
    ..The purpose of the current study was to analyze the patterns of relapse in these patients...
  30. pmc Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4287-92. 2009
    ..Expression levels were correlated with disease-free survival (DFS) and overall survival (OS). Interaction between this marker and paclitaxel efficacy was also examined...
  31. ncbi request reprint The role of radiation therapy as part of local-regional treatment in breast cancer patients with metastatic disease at diagnosis
    W Khodari
    Institut Gustave Roussy, Villejuif, France Université de Florence, Villejuif, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:1085. 2008
    ..We attempted to evaluate, in a large retrospective series, local control (LC) rates achieved by loco-regional radiation therapy (LRRT) alone or in combination with surgery...
  32. doi request reprint A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
    S Postel-Vinay
    1 The Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Institute of Cancer Research, London, UK 2 Département de médecine Unité INSERM 981, Institut Gustave Roussy, Villejuif, France
    Oncogene 32:5377-87. 2013
    ..This study suggests that PARP1/2 inhibitors as a monotherapy could represent a novel therapeutic strategy for NSCLC patients with ERCC1-deficient tumours...
  33. doi request reprint Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
    M Zoubir
    Translational Research Unit, UPRES EA035, Universite Paris XI, Institut Gustave Roussy, Villejuif
    Ann Oncol 19:1402-6. 2008
    ..Phosphorylation of serine 118 (ser118) has been reported to be involved in the activation of estrogen receptor (ER). In the present study, we evaluated whether endocrine therapy modulated ER phosphorylation on ser118...
  34. ncbi request reprint Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:3736-43. 1998
    ..To assess the outcome and the prognosis of adults with a neoplasm related to the Ewing's sarcoma family of tumors...
  35. ncbi request reprint DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Biochim Biophys Acta 1766:197-204. 2006
    ..Next, we will compare advantages and limitations of cohort-based and case-control studies. The choice of end-point to discriminate between sensitive and resistant patients will also be examined...
  36. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  37. ncbi request reprint One-stop breast unit: Acceptable levels of anxiety and good retention of information
    S Dauchy
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:20624. 2008
    ..We therefore prospectively explored emotional and cognitive states and functions of a consecutive series of patients (pts) seen at the One Stop Breast Unit of a single Institution...
  38. ncbi request reprint The role of the genomic breast cancer index in predicting pathologic complete response in breast cancer patients treated with neoadjuvant anthracycline plus taxane
    M C Mathieu
    Institut Gustave Roussy, Villejuif, France bioTheranostics, Inc, San Diego, CA Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:573. 2011
    ....
  39. ncbi request reprint Use of progesterone receptor (PR) expression to predict benefit from prolonged adjuvant tamoxifen (TAM) in breast cancer: Results of a biomarker study from the TAM01 randomized Trial
    M Mathieu
    Institut Gustave Roussy, Villejuif, France Centre Paul Baclesse, Caen, France
    J Clin Oncol 27:536. 2009
    ..Recent data suggest that a subset of patients could benefit from extended adjuvant TAM. The goal of this biomarker study was to identify potential candidates for extended TAM...
  40. ncbi request reprint Use of gene expression profiling to identify fibronectin 1 and MIG as candidate biomarkers for breast cancer screening
    E B Ruiz-Garcia
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:e22034. 2009
    ..Proteins concentrations were determined in blood samples by ELISA. Blood samples were from normal volunteers blood donors (n=119) and early breast cancer patients (n=133)...
  41. pmc Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening
    E Ruiz-Garcia
    Breast Cancer Translational Research Unit, UPRES EA03535, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 102:462-8. 2010
    ..There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene expression between BC samples and benign tumours was used to identify candidate biomarkers for blood-based screening...
  42. ncbi request reprint Risk factors for brain relapse in patients with metastatic breast cancer
    K Slimane
    Breast Cancer Unit, Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:1640-4. 2004
    ..The occurrence of brain metastases is an emerging problem in patients with metastatic breast cancer. In the present study, we looked at risk factors for brain metastasis among patients with metastatic breast cancer...
  43. doi request reprint Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
    N Berrada
    Department of Medical Oncology and INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii30-5. 2010
    ..Several other targeted agents are being developed in this setting, including epidermal growth factor receptor (EGFR), FGFR2, mammalian target of rapamycin (mTOR) and NOTCH inhibitors...
  44. ncbi request reprint Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure
    D Hawke
    UT M D Anderson Cancer Center, Houston, TX Institut Gustave Roussy, Villejuif, France M D Anderson Cancer Center, Houston, TX Marseille University, Marseille, France
    J Clin Oncol 27:e22072. 2009
    ..e22072 Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF / MS procedure...
  45. ncbi request reprint Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials
    C Mazouni
    Institut Gustave Roussy, Villejuif, France M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:1046. 2009
    ..In the present study, we assessed the efficacy of docetaxel in patients with metastatic breast cancer according to ER expression...
  46. ncbi request reprint Quality of life (QOL) after long-term follow-up in patients with early breast cancer (EBC)
    A Lot
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:20635. 2008
    ..The initial aim of this study was to assess the QOL of long-term survivors of early breast cancer, especially with regards to anthracycline therapy...
  47. ncbi request reprint BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes?
    S Delaloge
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:574. 2008
    ..We therefore aimed at assessing the in vivo sensitivity of BRCA1-related BC to both a FAC/FEC-type regimen and a more recent FEC-Taxane sequential regimen...
  48. ncbi request reprint Determinants of therapeutic delays and their impact on axillary node involvement in operable invasive breast cancer (BC) patients (pts)
    D Dionysopoulos
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:615. 2009
    ..We explored the potential impact of STI on a surrogate of survival, axillary nodal involvement (N+), among 1,000 recently diagnosed BC pts, as well as the causes of potential delays...
  49. ncbi request reprint Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer
    F Andre
    Insitut Gustave Roussy, Villejuif, France M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:569. 2009
    ..569 Background: In the present study, we have analyzed dysregulated pathways in triple-negative breast cancers...
  50. doi request reprint Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
    M Arnedos
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:2293-9. 2012
    ....
  51. pmc A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
    B Dutta
    Department of Systems Biology Unit 950, The University of Texas MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA
    Br J Cancer 106:1107-16. 2012
    ..For example, diverse transcriptomic and gene copy number variation data are currently collected for various cancers, but relatively few current methods are capable to utilise the emerging information...
  52. ncbi request reprint Tumor-derived exosomes: a new source of tumor rejection antigens
    F Andre
    Unite d immunologie, Immunology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, F 94805 Villejuif Cedex, France
    Vaccine 20:A28-31. 2002
    ..Here, we will describe the biochemical properties of tumor-derived exosomes and, their pre-clinical activity as cancer vaccines...
  53. ncbi request reprint A study of the immunological response to tumor ablation with irreversible electroporation
    B Al-Sakere
    UMR 8121 CNRS Institut, Gustave Roussy, 39 Rue C Desmoulins, F 94805 Villejuif, France
    Technol Cancer Res Treat 6:301-6. 2007
    ..We confirm here that immune response is not instrumental in irreversible electroporation efficacy, and we propose that irreversible electroporation may be, therefore, a treatment modality of interest to immunodepressed cancer patients...
  54. doi request reprint Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  55. doi request reprint Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer
    Catherine Uzan
    Research Translational Laboratory, Histocytopathology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, Villejuif, France
    Cancer 117:32-9. 2009
    ..The objective of the current study was to evaluate the quality and potential use of material obtained from fine-needle aspiration cytology (FNAC)...
  56. doi request reprint CXCR4 expression in early breast cancer and risk of distant recurrence
    Fabrice Andre
    Breast Medical Oncology Unit, Department of Radiation Therapy, Department of Pathology and Translational Research Unit UPRES EA03535, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Oncologist 14:1182-8. 2009
    ..e., liver, lung, brain, and bone)...
  57. doi request reprint EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
    D Planchard
    Department of Medical Oncology, Gustave Roussy, Villejuif
    Ann Oncol 26:2073-8. 2015
    ..Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients...
  58. pmc Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
    T Yamazaki
    1 INSERM U1015, Villejuif, France 2 Institut de Cancérologie Gustave Roussy, Villejuif, France 3 University of Paris Sud XI, Villejuif, France
    Cell Death Differ 21:69-78. 2014
    ..These findings underscore the potential clinical utility of combination regimens involving immunogenic chemotherapy and certain TLR4 agonists in advanced HMGB1-deficient cancers. ..
  59. pmc A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
    F Farace
    Translational Research Laboratory, Institut de Cancerologie Gustave Roussy, 94805 Villejuif, France
    Br J Cancer 105:847-53. 2011
    ..However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay)...
  60. pmc Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
    C Mazouni
    Laboratoire de transfert biologique et oncologique, Marseille University, Houston, TX, USA
    Br J Cancer 99:68-71. 2008
    ..In conclusion, patients with breast cancer have elevated levels of collagen IV compared to healthy women and collagen IV levels increase further during chemotherapy...
  61. ncbi request reprint Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
    Fabrice Andre
    Breast Cancer Unit and Translational Research Unit, UPRES03535, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:2061-7. 2007
    ..A molecular marker may be prognostic of outcome or predictive of response to therapy, or a combination of both...
  62. doi request reprint Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:2636-43. 2008
    ..The aim of the present study was to assess the efficacy of adjuvant docetaxel and anthracycline therapy according to ER expression in two randomized clinical trials...
  63. ncbi request reprint A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer
    F Andre
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Centre René Gauducheau, Saint Herblain, France Institut Claudius Regaud, Toulouse, France Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA Royal Marsden Hospital, London, United Kingdom University of California San Francisco, San Francisco, CA Novartis Pharmaceuticals Corporation, East Hanover, NJ Novartis Pharma AG, Basel, Switzerland Massachusetts General Hospital, Boston, MA
    J Clin Oncol 29:508. 2011
    ..Dovitinib (TKI258) is a tyrosine kinase inhibitor that targets FGFR, VEGFR, and PDGFR. In pc models, dovitinib demonstrated potent antitumor activities in FGFR1-amplified tumor cell lines...
  64. ncbi request reprint Anticancer effects of polyadenylic-polyuridylic acid (poly[A:U]) and uncoupling of chemokine receptor signaling: Role of CCR5 and CXCR3
    R Conforti
    Institut Gustave Roussy, Villejuif, France INNATE PHARMA, Marseille, France
    J Clin Oncol 27:3063. 2009
    ..3063 Background: Several tumor cells express toll-like receptors (TLRs) which constitute putative therapeutic targets...
  65. ncbi request reprint Impact of chemotherapy on the nutritional status and quality of life during treatment for breast cancer
    S Antoun
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:20674. 2008
    ..The aim of this study was to analyze the consequences of adjuvant CT on the nutritional status and QOL during breast cancer...
  66. ncbi request reprint Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
    F Andre
    Institut Gustave Roussy, Villejuif, France Centre Regional Rene Gauducheau, Nantes, France University of California Los Angeles, Los Angeles, CA Novartis Pharmaceuticals, Basel, Switzerland Emory University School of Medicine, Atlanta, GA
    J Clin Oncol 26:1003. 2008
    ..This phase I trial addresses the safety and efficacy of a combination between paclitaxel, trastuzumab and RAD001 in patients previously treated with trastuzumab and taxanes...
  67. doi request reprint Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
    S Guiu
    Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France
    Ann Oncol 23:2997-3006. 2012
    ..Methods for breast cancer classification into molecular subtypes should, however, be incorporated into clinical trial design...
  68. ncbi request reprint A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
    E Massarelli
    MD Anderson Cancer Center, Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, P O Box 432, Houston, TX 77030, USA
    Lung Cancer 39:55-61. 2003
    ..02). This review highlights the need for novel therapy approaches for patients with recurrent NSCLC who have failed second-line therapy and provides a baseline for the statistical design of such studies...
  69. doi request reprint Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  70. ncbi request reprint Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Pharm Res 23:1951-8. 2006
    ....
  71. ncbi request reprint Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Nat Clin Pract Oncol 3:621-32. 2006
    ..This Review describes the current limitations and future promises of gene-expression-based molecular classification of breast cancer and how it might impact on selection of adjuvant therapy for individual patients...
  72. ncbi request reprint Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  73. ncbi request reprint Impact of the mode of estrogen receptor determination on breast cancer prognosis
    P Martin
    Marseille University, Marseille, France Institut Gustave Roussy, Villejuif, France Clinique Beauregard, Marseille, France
    J Clin Oncol 27:e11609. 2009
    ....
  74. ncbi request reprint Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy
    W F Symmans
    University of Texas M D Anderson Cancer Center, Houston, TX Institut Gustave Roussy, Villejuif, France Georgetown Lombardi Comprehensive Cancer Center, Washington, DC Institut Gustave Roussy, Villejuif, France General Hospital Leoben, Leoben, Austria Oncology Institute, University of Ljubljana, Ljubljana, Slovenia University of Graz, Graz, Austria Nuvera Biosciences Inc, Woburn, MA
    J Clin Oncol 29:1030. 2011
    ....
  75. ncbi request reprint Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1
    J Pierga
    Institut Curie, Paris, France Institut Gustave Roussy, Villejuif, France Paul Strauss Cancer Center, Strasbourg, France Institut Claudius Regaud, Toulouse, France Centre François Baclesse, Caen, France CRLC Val d Aurelle, Montpellier, France Centre Oscar Lambret, Universite Lille Nord de France, Lille, France Centre Antoine Lacassagne, Nice, France Centre Eugène Marquis, Rennes, France FNCLCC, Paris, France Institut Paoli Calmettes, Marseille, France
    J Clin Oncol 29:10510. 2011
    ..Changes in the CTC HER2 status compared to primary tumor have been reported. Predictive value of CEC for response to anti-angiogenic agents is debated...
  76. ncbi request reprint Use of immunohistochemical evaluation of DNA repair proteins to demonstrate cisplatin response prediction in resected NSCLC squamous cell carcinoma
    W E Pierceall
    On Q ity, Waltham, MA CHU Grenoble, Grenoble, France Department of Medicine I, Medical University Vienna, Vienna, Austria Medical University of Graz, Graz, Austria Medical University of Vienna, Vienna, Austria Brigham and Women s Hospital, Boston, MA Institut Gustave Roussy, Villejuif, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:10579. 2011
    ..Additionally, biomarker expression may be utilized to define treatment of histological subclasses of NSCLC...
  77. doi request reprint Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    J C Soria
    Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France
    Ann Oncol 25:2244-51. 2014
    ..Several tumor types, including breast carcinoma, demonstrate amplification of fibroblast growth factor (FGF)-related genes. There are no approved drugs for molecularly defined FGF-aberrant (FGFR1- or FGF3/4/19-amplified) tumors...
  78. doi request reprint Prioritizing targets for precision cancer medicine
    F Andre
    Department of Medical Oncology, INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France
    Ann Oncol 25:2295-303. 2014
    ....
  79. pmc Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
    M V Dieci
    INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 25:611-8. 2014
    ....
  80. ncbi request reprint Exosomes for cancer immunotherapy
    F Andre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:iv141-4. 2004
  81. ncbi request reprint Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  82. ncbi request reprint Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast
    Julien Grenier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif
    Anticancer Res 27:547-55. 2007
    ..Pure or metaplastic squamous cell carcinoma (SCC) of the breast is a rare entity with an unclear pathogeny and aggressive clinical behaviour. An attempt was made to characterize its differential immunohistochemical and biological profile...
  83. ncbi request reprint Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  84. ncbi request reprint Malignant effusions and immunogenic tumour-derived exosomes
    Fabrice Andre
    Departments of Clinical Biology, Immunology Unit, Institut Gustave Roussy, Villejuif, France
    Lancet 360:295-305. 2002
    ..To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells...
  85. pmc Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
    Rene Natowicz
    AP HP, Hopital Tenon, Department of Gynecology, 4 rue de la Chine, F 75020 Paris, France
    BMC Bioinformatics 9:149. 2008
    ..Multigenic predictors were designed by selecting probe sets highly ranked in their predictions and tested using several validation sets...